

MAY 27 2009

USSN 09/890,335
Response to Office Action mailed January 26, 2009
Amendment filed May 26, 2009

Amendments to the Specification

Please replace the paragraph occurring at page 1 lines 27-33 with the following amended paragraph:

Several documents are cited throughout the text of this specification. Each of the documents cited herein (including any manufacturer's specifications, instructions, etc.) are hereby incorporated by reference; however, there is no admission that any document cited is indeed prior art of the present invention. Further incorporated by reference is the complete disclosure content of the co-pending application filed in the name of IDEA AG and bearing the title "Transnasal transport/immunization with highly adaptable carriers" (U.S. Application No. 09/890,371, published as WO 2000/044350).

Please replace the paragraph occurring at page 14 line 30 to page 15 line 2 with the following amended paragraph:

For further definitions, especially such pertaining to the penetrants in terms of complex body deformability, the corresponding mechanism of action, lists of interesting penetrant ingredients or selected agents it is referred to the issued or pending patents (DE 41 07 152, PCT/EP91/01596 (published as WO/1992/003122 and equivalent to U.S. Patent No. 6,165,500 A), PCT/EP96/04526 (published as WO/1998/17255 and equivalent to U.S. Publication No. 2002/048596), DE 44 47 287). Detailed information relevant for the manufacturing process and penetrant loading with the antigenic (macro)molecules and/or immunoadjuvants, which are too big to permeate through the barrier, can be found in international patent application PCT/EP98/06750 (published as WO 00/24377 and equivalent to U.S. Publication No. 2008/279815).

Please replace the paragraph occurring at page 20 lines 26-32 with the following amended paragraph:

Basic formulations suitable for achieving the desired goals are known in the art: see, e.g., DE 41 07 152, PCT/EP91/01596 (published as WO/1992/003122 and equivalent to U.S. Patent No. 6,165,500 A), PCT/EP96/04526 (published as WO/1998/17255 and equivalent to U.S. Publication No. 2002/048596), DE 44 47 287, for more detailed or complementary information. The vaccine of this invention is not useful just for prophylactic or therapeutic vaccination but, moreover, is applicable for the treatment of allergy and for obtaining immunity against microbes, including extracellular and intercellular bacteria, viruses and parasites in the human and veterinary medicine.

Please replace the paragraph occurring at page 43 lines 16-17 with the following amended paragraph:

The effect discussed with examples 22-23 was confirmed also with a blend of different cytokines. ~~The results are shown in figure 10.~~